Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 401
- Registration Number
- NCT04674956
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China
🇨🇳Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Zhongshan Hospital, Shanghai, Shanghai, China
Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Junling Li
- Target Recruit Count
- 30
- Registration Number
- NCT04670913
- Locations
- 🇨🇳
China, Beijing, Beijing, China
Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2021-08-23
- Target Recruit Count
- 337
- Registration Number
- NCT04654403
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Hospital of Stomatology, Wuhan University
- Target Recruit Count
- 68
- Registration Number
- NCT04649476
- Locations
- 🇨🇳
Hospital of Stomatology, Wuhan University, Wuhan, Hubei, China
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
- Conditions
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 687
- Registration Number
- NCT04639180
- Locations
- 🇨🇳
Guangxi Medical University Affiliated Tumor Hospital, Nanjin, Guangzhou, China
🇨🇳The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Efficacy and Safety of Camrelizumab in Real-World Study
- Conditions
- Interventions
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 450
- Registration Number
- NCT04631146
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
- Conditions
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 600
- Registration Number
- NCT04627012
- Locations
- 🇨🇳
Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- Peking University
- Target Recruit Count
- 1030
- Registration Number
- NCT04616040
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT04583020
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2020-10-01
- Target Recruit Count
- 46
- Registration Number
- NCT04572542
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.